PharmacoMicrobiomics: The Drug-Microbiome Portal

How Bugs Modulate Drugs?

Launched on 11/11/11; Current Release 1.5 (21 Mar 2021): Spring of Hope! (Release History)

Detailed View

Summary Gut microbes (superkingdom: Bacteria) increase Atorvastatin's activity.
Atorvastatin (PubChem CID: 60823)
Bacteria (Tax ID: 2)
increase activity
Atorvastatin shows unexplained interindividual variability in lowering blood cholesterol levels in humans. In an experiment, conventional mice and antibiotic-treated mice, put on standard chow diet (SCD) or high-fat diet (HFD), were treated with atorvastatin. Results show - Minimal effect of atorvastatin in antibiotic-treated mice, compared to conventional mice - Dysbiosis resulting high Firmicutes and low Bacteroidetes in mice fed with high-fat-diet, which was partially reserved after atorvastatin treatment - Clostridium coccoides were more abundant in the high-fat diet group, and returned to normal or even above normal after atorvastatin. - The expression of hepatic and intestinal genes responsible for cholesterol metabolism, including Ldlr, Srebp2, and Npc1l1, was lowered in the gut microbiota-depleted mice.

Browse Drug-Microbiome Relationship